Australian-New Zealand Clinical Trial: Plasmalogen supplementation for cognitive function in adolescents with Postural Orthostatic Tachycardia Syndrome (POTS): a pilot study.

Australia, Oct. 28 -- The Australian New Zealand Clinical Trials Registry (ANZCTR) received information related to the study titled ‘Plasmalogen supplementation for cognitive function in adolescents with Postural Orthostatic Tachycardia Syndrome (POTS): a pilot study.’. The following are the other relevant details related to the trial:

Trial ID: 392791

Submit Date: 10/8/26 11:18

Study Type: Interventional

Intervention: Participants randomised to the intervention arm will receive oral Hokkaido Scallop Oil Plasmalogen (HSOP). Each capsule contains 0.5 mg of scallop-oil-derived plasmalogens. Participants will consume two capsules daily (total plasmalogen dose: 1.0 mg/day) with meals for 90 consecutive days, in addition to their usual stand...